2020 Value Assessment Framework
In January 2020, ICER will issue an update to the framework that underpins our evidence reports on new drugs and other health care interventions. ICER’s value framework is the product of more than 10 years’ experience working with all participants in the health care system to develop methods to assess the comparative clinical effectiveness and the comparative value of health care tests, treatments, and delivery system innovations. The current iteration of the framework has guided ICER’s assessments from 2017 to 2019.
To inform the planned update, ICER will open a national call for suggestions on how to improve our value assessment framework. Based on the feedback we receive, we plan to publish draft revisions to our value assessment framework on August 21st, welcome public comment on those proposed revisions through October 18th, and post our final updated framework on January 31st. This final framework will be applied to all assessments initiated in 2020 and beyond.
For questions, please contact email@example.com.
ICER’s Value Framework and Patient Feedback: Q&A with Steve Pearson (Webinar Recording | Webinar Q&A Responses )
September 4, 2019
ICER conducted a fireside chat moderated by Tanisha Carino, ICER Board member and Executive Director of FasterCures, with Steve Pearson, ICER’s Founder and President. This hour-long conversation explored the mission of ICER, with an emphasis on ICER’s Value Assessment Framework revisions. Hear about the suggestions ICER received as part of its recent public comment period, proposed changes, and how you and your organization can continue to be part of improving our process. This webinar was intended for patient organizations and was open to the public.
ICER is also working on the “Valuing a Cure” initiative:
ICER is simultaneously developing methods adaptations to its value framework to be applied in the assessment of potential cures and other treatments that qualify as “single or short-term transformative therapies,” or SSTs. While these proposals do not fundamentally alter ICER’s approach to value assessment, they are intended to equip decision makers with a more reliable and transparent evaluation of SSTs’ uncertainty, value, and value-based pricing. Please see the site on cures here.